Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/17/24
End: 12/31/29
Due: 12/31/30
Phase: N/A
Priority: Normal
Start: 04/21/23
End: 03/01/33
Due: 03/01/34
Phase: N/A
Priority: Normal
Start: 09/30/22
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 03/30/23
End: 12/31/31
Due: 12/31/32
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | NCT06120972 | Alexander B Olawaiye, MD | user2@example.com | None | 2024-01-17 | 2029-12-31 | 2030-12-31 | - | - | 2025-07-14 |
| ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | NCT05071937 | Alexander B Olawaiye, MD | user2@example.com | None | 2023-04-21 | 2033-03-01 | 2034-03-01 | - | - | 2025-07-14 |
| T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors | NCT05200559 | Alexander B Olawaiye, MD | user2@example.com | None | 2022-09-30 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |
| Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | NCT05467670 | Alexander B Olawaiye, MD | user2@example.com | None | 2023-03-30 | 2031-12-31 | 2032-12-31 | - | - | 2025-07-14 |